Mechanism of action
Quinine accumulates in the acidic food vacuole of intraerythrocytic malarial parasites, primarily Plasmodium falciparum. The parasite digests hemoglobin to obtain amino acids, releasing toxic free heme in the process. Normally, the parasite detoxifies heme by polymerizing it into inert hemozoin crystals.
Quinine inhibits heme polymerase, preventing the conversion of toxic heme into hemozoin. The accumulation of free heme damages parasite membranes and proteins, leading to parasite death. Quinine also intercalates into parasite DNA, further disrupting replication.
Additionally, quinine has a quinidine-like effect on cardiac tissue, blocking sodium and potassium channels, which accounts for its arrhythmogenic potential. It also increases acetylcholine release at the neuromuscular junction and decreases the refractory period of skeletal muscle, explaining its historical use (now discouraged) for muscle cramps.
- Quinine inhibits heme polymerase in Plasmodium, causing toxic heme accumulation and parasite death.
- Cinchonism (tinnitus, hearing loss, visual disturbances) is the classic adverse effect at therapeutic doses.
- Quinine causes QT prolongation and torsades de pointes due to quinidine-like Class Ia antiarrhythmic effects.
- Hypoglycemia results from quinine-induced pancreatic insulin secretion, especially in pregnancy and severe malaria.
- Immune-mediated thrombocytopenia is a serious, potentially fatal adverse effect; FDA warns against use for leg cramps.
- Quinine is contraindicated in G6PD deficiency due to risk of severe hemolytic anemia.
- Artesunate has replaced quinine as first-line treatment for severe falciparum malaria in most guidelines.
- Quinine is metabolized by CYP3A4; ritonavir and other inhibitors increase toxicity risk.
Indications
Approved uses
- Severe or complicated falciparum malaria: particularly chloroquine-resistant P. falciparum malaria, often in combination with doxycycline, clindamycin, or other antimalarials
- Uncomplicated malaria in regions without access to artemisinin-based combination therapy (ACT), though ACTs are now preferred first-line globally
- Babesiosis (off-label, in combination with clindamycin)
Off-label uses
- Nocturnal leg cramps: FDA has warned against this use due to serious adverse effects (thrombocytopenia, cardiac arrhythmias) outweighing modest benefit
Quinine is not recommended for malaria prophylaxis due to toxicity and availability of safer alternatives. Artesunate has largely replaced quinine as first-line therapy for severe malaria in many settings due to superior efficacy and safety.
Pharmacokinetics
- Absorption: Well absorbed orally; bioavailability ~80%
- Distribution: Widely distributed; crosses the placenta and enters breast milk; protein binding ~70-95% (primarily to α1-acid glycoprotein, which increases in malaria)
- Metabolism: Hepatic via CYP3A4 and CYP2C19 to inactive metabolites
- Excretion: Renal (~20% unchanged); elimination half-life 8-14 hours in healthy individuals, prolonged in severe malaria and renal impairment
- Special populations: Clearance is reduced in pregnancy (despite increased volume of distribution), severe malaria, and hepatic or renal impairment; dose adjustment follows product label and clinical monitoring
Adverse effects
Cinchonism (dose-related)
The classic toxicity syndrome occurring at therapeutic or slightly supratherapeutic levels:
- Tinnitus (ringing in the ears)
- Hearing loss (reversible or permanent)
- Visual disturbances: blurred vision, diplopia, photophobia, altered color perception
- Headache, dizziness, nausea, vomiting, abdominal pain
- Vertigo and confusion
Hematologic
- Thrombocytopenia: immune-mediated, can be severe and life-threatening (black box warning in some countries)
- Hemolytic anemia: especially in patients with G6PD deficiency or blackwater fever
- Disseminated intravascular coagulation (DIC)
Cardiovascular
- QT prolongation and torsades de pointes: quinine has quinidine-like Class Ia antiarrhythmic effects
- Hypotension (particularly with rapid IV infusion)
- Conduction disturbances
Metabolic
- Hypoglycemia: quinine stimulates pancreatic insulin release; particularly dangerous in pregnancy and severe malaria
Hypersensitivity
- Rash, urticaria, angioedema
- Thrombotic thrombocytopenic purpura (TTP)
- Photosensitivity
Other
- Hepatotoxicity (rare)
- Renal impairment (rare)
- Fetal complications: auditory nerve damage, visual impairment, limb abnormalities (use only when benefit outweighs risk)
Contraindications and warnings
Absolute contraindications
- Known hypersensitivity to quinine or other cinchona alkaloids (quinidine)
- G6PD deficiency (relative; risk of severe hemolysis)
- Optic neuritis
- Tinnitus or hearing loss
- Myasthenia gravis (may precipitate crisis)
- Concomitant use with ritonavir, saquinavir, or other drugs causing significant CYP3A4 inhibition leading to toxic quinine levels
Black box warnings and serious risks
- Thrombocytopenia: severe, potentially fatal; FDA advises against use for leg cramps
- QT prolongation: avoid in congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, or with other QT-prolonging drugs
- Hemolytic uremic syndrome and TTP
Pregnancy and lactation
- Pregnancy category C (US, historical): quinine crosses the placenta and has been associated with auditory nerve hypoplasia, visual defects, and limb abnormalities (high doses). However, it is used when severe malaria poses greater maternal and fetal risk than drug toxicity.
- Lactation: excreted in breast milk; use with caution
Special populations
- Renal/hepatic impairment: dose adjustment and monitoring required
- Elderly: increased risk of cardiac and CNS toxicity
Drug interactions
CYP450 interactions
- CYP3A4 inhibitors (ritonavir, ketoconazole, erythromycin): increase quinine levels, risk of toxicity and QT prolongation
- CYP3A4 inducers (rifampin, phenytoin, carbamazepine): decrease quinine levels, risk of treatment failure
- Quinine inhibits CYP2D6, raising levels of codeine, tamoxifen, and tricyclic antidepressants
Pharmacodynamic interactions
- QT-prolonging agents (macrolides, fluoroquinolones, antipsychotics, Class Ia and III antiarrhythmics): additive QT prolongation and torsades risk
- Digoxin: quinine increases digoxin levels (reduces renal clearance)
- Warfarin: quinine may potentiate anticoagulant effect
- Neuromuscular blockers: quinine may potentiate effects, prolonging paralysis
- Mefloquine: increased risk of seizures and cardiac toxicity; avoid coadministration
- Antacids and aluminum-containing compounds: may decrease quinine absorption; separate administration
Other antimalarials
- Often combined with doxycycline or clindamycin to enhance efficacy and reduce resistance
- Avoid combination with halofantrine (additive cardiotoxicity)
Clinical pearls
- Artesunate has replaced quinine as first-line therapy for severe malaria in most guidelines due to faster parasite clearance and lower mortality.
- Cinchonism is reversible with dose reduction or discontinuation in most cases, but hearing loss can be permanent.
- Monitor blood glucose closely during treatment, especially in pregnancy and severe malaria, due to hyperinsulinemia.
- Quinine stimulates uterine contractions and has been historically misused as an abortifacient; it is considered safe for malaria treatment in pregnancy when indicated.
- Blackwater fever (massive intravascular hemolysis with hemoglobinuria) is a rare, life-threatening complication historically linked to quinine use in sensitized individuals.
- The FDA banned quinine for leg cramps in 2006 due to unfavorable risk-benefit ratio; compounded quinine products are not approved.
- Therapeutic drug monitoring is not routinely available but may be useful in severe toxicity or renal/hepatic impairment.
- Quinine has a narrow therapeutic index; cinchonism often occurs at or near therapeutic doses.
- EKG monitoring is recommended during IV administration due to risk of arrhythmias.
- Oral quinine sulfate is still used in resource-limited settings where artesunate is unavailable.
QUININE causes Cinchonism: Quiet (hearing loss), Upset vision, Insulin release (hypoglycemia), Nausea, Irregular heart rhythm (QT prolongation), Numb/tingling, Extended QT.
Practice questions
1. A 32-year-old aid worker returns from West Africa with high fever, rigors, and altered mental status. Blood smear shows ring forms and schizonts of Plasmodium falciparum with 8% parasitemia. IV quinine is initiated. Six hours later, the patient becomes diaphoretic and confused. Finger-stick glucose is 38 mg/dL. Which mechanism best explains this complication?
2. A 45-year-old man with severe falciparum malaria is treated with IV quinine. On day 3, he reports persistent ringing in his ears and blurred vision. Audiometry confirms bilateral high-frequency hearing loss. Which adverse effect is this patient experiencing?
3. A 28-year-old pregnant woman at 30 weeks gestation is treated with quinine for severe malaria. She develops palpitations, and an ECG shows QTc of 520 ms with a polymorphic wide-complex tachycardia. Which property of quinine explains this arrhythmia?
Frequently asked questions
How does quinine work against malaria?
Quinine inhibits heme polymerase in the Plasmodium parasite's food vacuole, preventing detoxification of toxic heme released during hemoglobin digestion. The accumulation of free heme damages parasite membranes and proteins, killing the parasite. It also intercalates into parasite DNA, disrupting replication. Quinine is primarily effective against intraerythrocytic stages of Plasmodium falciparum.
What are the side effects of quinine?
The most common adverse effect is cinchonism: tinnitus, hearing loss, visual disturbances, headache, nausea, and vertigo. Serious side effects include immune-mediated thrombocytopenia, QT prolongation and torsades de pointes, hypoglycemia from insulin release, and hemolytic anemia especially in G6PD deficiency. Rapid IV infusion can cause hypotension. Cinchonism is often reversible, but hearing loss may be permanent.
Is quinine still used for malaria?
Yes, but its use has declined significantly. Artesunate is now first-line for severe falciparum malaria in most guidelines due to superior efficacy and safety. Quinine is still used in regions where artesunate is unavailable or for uncomplicated malaria in combination with doxycycline or clindamycin. It is no longer recommended for malaria prophylaxis or for leg cramps due to toxicity concerns.
Can quinine cause low blood sugar?
Yes, quinine stimulates pancreatic beta cells to release insulin, causing hyperinsulinemia and subsequent hypoglycemia. This is particularly dangerous in pregnant women and patients with severe malaria, who may already have impaired glucose regulation. Blood glucose should be monitored closely during quinine therapy, especially with IV administration. Hypoglycemia can be severe and life-threatening if not recognized and treated promptly.
Quinine vs chloroquine — what is the difference?
Both are antimalarials that inhibit heme polymerization, but quinine is derived from cinchona bark while chloroquine is synthetic. Quinine is used for severe or chloroquine-resistant falciparum malaria, whereas chloroquine is first-line for sensitive P. falciparum and other Plasmodium species. Quinine causes cinchonism and QT prolongation; chloroquine causes retinopathy with chronic use. Chloroquine has a longer half-life and is used for prophylaxis; quinine is not.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: P01BC01
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.